Stockscreener 앱 받기
0.6895
2.91%
0.0195
시간 외 거래:
.65
-0.0395
-5.73%
전일 마감가:
$0.67
열려 있는:
$0.627
하루 거래량:
808.14K
Relative Volume:
0.68
시가총액:
$4.69M
수익:
-
순이익/손실:
$-6.07M
주가수익비율:
-0.1193
EPS:
-5.78
순현금흐름:
$-7.34M
1주 성능:
-3.43%
1개월 성능:
+8.91%
6개월 성능:
-31.73%
1년 성능:
-59.44%
1일 변동 폭
$0.62
$0.72
1주일 범위
$0.62
$1.21
52주 변동 폭
$0.5759
$3.00
Adial Pharmaceuticals Inc Stock (ADIL) Company Profile
명칭
Adial Pharmaceuticals Inc
전화
434-422-9800
주소
1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
ADIL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADIL
Adial Pharmaceuticals Inc
|
0.6895 | 4.69M | 0 | -6.07M | -7.34M | -5.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Adial Pharmaceuticals Inc Stock (ADIL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2018-10-30 | 개시 | Maxim Group | Buy |
| 2018-10-11 | 개시 | Dawson James | Buy |
Adial Pharmaceuticals Inc 주식(ADIL)의 최신 뉴스
ADIL: Adial Pharmaceuticals Boosts Patent Portfolio with New Approval | ADIL Stock News - GuruFocus
Geode Capital Management LLC Grows Stock Holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Adial Pharmaceuticals secures $2.75 million through warrant exercise - Investing.com
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds | ADIL Stock News - GuruFocus
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds - GlobeNewswire
Healthcare Investor Commits $2.75M to Adial Pharmaceuticals Addiction Treatment Pipeline - Stock Titan
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring - Asianet Newsable
Adial Pharmaceuticals Inc: Rising -76.71% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
How will Adial Pharmaceuticals Inc’s (ADIL) earnings compare to estimates this quarter? - uspostnews.com
Adial Pharmaceuticals (ADIL) Secures Patent for Novel Addiction Treatment Method | ADIL Stock News - GuruFocus
Adial Pharmaceuticals secures patent for addiction treatment - Investing.com
Adial Pharmaceuticals Expands Intellectual Property - GlobeNewswire
Revolutionary Patent Links Genetic Markers to Personalized Addiction Treatment Success - Stock Titan
EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders - Benzinga
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals CEO Weighs in on the Alcohol Pandemic and Drunk Driving Over the Holidays; FOX31 Denver's Shaul Turner Interviews Bill Stilley - ACCESS Newswire
Adial Completes Validation of Genetic Biomarker Test in Collaboration with Eurofins for Upcoming Phase 3 Trial - ACCESS Newswire
Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility - ACCESS Newswire
Adial Pharma stock hits 52-week low at $0.6 amid market challenges - Investing.com Australia
Adial Pharma stock hits 52-week low at $0.6 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Announces Open Market Purchases of Common Stock by Chief Medical Officer, Bankole Johnson, M.D. - ACCESS Newswire
Adial Pharmaceuticals Commences Phase 3 Trial of AD04 for Alcohol Use Disorder - ACCESS Newswire
Alcohol Use Disorder Treatment Market: Discover the Best - openPR.com
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 19.8% in March - Defense World
Adial Pharmaceuticals Appoints Tony Goodman as COO - TipRanks
Adial Pharmaceuticals appoints new COO Tony Goodman - Investing.com
Litchfield Hills Research Predicts ADIL Q1 Earnings - Defense World
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 610.2% - Defense World
Adial Pharma stock hits 52-week low at $0.69 amid market challenges - Investing.com
Brookline Capital Management Estimates ADIL Q1 Earnings - Defense World
Rodman & Renshaw maintains Adial stock Buy rating, $8 target By Investing.com - Investing.com Australia
Rodman & Renshaw maintains Adial stock Buy rating, $8 target - Investing.com India
Adial Pharma stock hits 52-week low at $0.71 amid market challenges - Investing.com
Adial Pharma stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update - GlobeNewswire
ADIAL PHARMACEUTICALS, INC. SEC 10-K Report - TradingView
Adial Pharmaceuticals expects cash to fund operations into 2H of 2025 - TipRanks
Can Adial's FDA-Approved Strategy for Alcohol Treatment Offset Its Widening Losses? - StockTitan
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Grows By 59.2% - The AM Reporter
Adial Pharmaceuticals Files for Expedited Review of AD04 with the FDA - ACCESS Newswire
Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits - ACCESS Newswire
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia - accessnewswire.com
Adial Pharmaceuticals Receives Positive FDA Feedback on In Vitro Bridging Strategy for AD04 - Defense World
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland - ACCESS Newswire
Adial gets FDA nod for Phase 3 drug strategy By Investing.com - Investing.com Australia
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs - AOL.com
Adial gets FDA nod for Phase 3 drug strategy - Investing.com India
Adial Pharmaceuticals Receives Positive Response from FDA - GlobeNewswire
Adial Pharmaceuticals Inc (ADIL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):